Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Director | June 10, 2026 | June 11, 2026 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Director | June 11, 2019 | June 12, 2019 |
| Viracta Therapeutics, Inc.VIRX · Entity 85616 | Director | June 09, 2022 | June 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.43 · Expires 2036-06-09 | Direct | 5,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Sierra Oncology, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-06-11 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.
Viracta Therapeutics, Inc.
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2032-06-09 | Direct | 40,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:07 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001193125-26-267518 · ownership.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 14 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F8 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 13 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F8 · price: The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price. F7 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $15.36 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 12 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,100 shares Expires 2034-06-11 F6 · price: The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,100 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 11 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2034-06-11 F6 · price: The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $32.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 10 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2033-06-11 F5 · price: The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 9 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2033-06-11 F5 · price: The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $39.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 8 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2032-06-09 F4 · price: The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 7 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2032-06-09 F4 · price: The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 611 | Not disclosed Strike: $60.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 6 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 611 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 611 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 5 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 611 Underlying: Common Stock · 611 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,107 | Not disclosed Strike: $60.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 4 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,107 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,107 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 3 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,107 Underlying: Common Stock · 1,107 shares Expires 2032-03-23 F3 · price: The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 1,393 | Not disclosed Strike: $83.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 2 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,393 shares Expires 2031-12-13 F2 · price: The reporting person agreed to cancellation of an option granted on December 14, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:14 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,393 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321154 · ownership.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,393 Underlying: Common Stock · 1,393 shares Expires 2031-12-13 F2 · price: The reporting person agreed to cancellation of an option granted on December 14, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 27, 2025 Filed Jul 2, 2025 20:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 1,100 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0000950170-25-092939 · ownership.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2035-05-26 F1 · derivative.exercise_price: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F2 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. F1 · derivative.underlying_shares: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. F1 · balance_after: On June 6, 2025, the Company effected a 1-for-20 reverse stock split of its common stock. All share and exercise price amounts reported herein reflect the reverse stock split. Prior to the reverse stock split, the reporting person was granted options to purchase 22,000 shares at an exercise price of $0.3200 per share. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 22:59 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0000950170-24-073906 · ownership.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 21:20 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-037115 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 12, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 22:26 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001209191-22-036088 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2022 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 17:07 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001209191-22-036010 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 12,227 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012459 · doc4.xml · derivative · entry 2 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,227 Underlying: Common Stock · 12,227 shares Expires 2032-03-23 F2 · derivative.exercise_date: The shares subject to this option shall vest on the one-year anniversary of June 10, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 19:19 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 22,140 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0000899243-22-012459 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,140 Underlying: Common Stock · 22,140 shares Expires 2032-03-23 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/36th of the total number of shares on each monthly anniversary of December 14, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 21:20 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 27,860 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0000899243-21-048601 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,860 Underlying: Common Stock · 27,860 shares Expires 2031-12-13 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/36th of the total number of shares on each monthly anniversary of December 14, 2021 (the "Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the three-year anniversary of the Vesting Commencement Date; provided, however that the option will vest in full upon a change in control of the Issuer. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 20:25 UTC | Viracta Therapeutics, Inc. VIRX · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $8.74 | $0.00 |
DisclosureSEC source: 0001209191-21-023665 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-26 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 1, 2021 (the "Vesting Commencement Date"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 17:05 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000899243-20-018141 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal monthly installments over a one (1) year period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 14:29 UTC | Viracta Therapeutics, Inc. SNSS · Entity 85616 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0000899243-19-024443 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-09-30 F1 · derivative.exercise_date: The option shall vest and become exercisable in twenty-four (24) equal monthly installments over a two (2) years period following the date of grant subject to the Reporting Person's continuous service on the Board through each such vesting date. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 17:52 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001209191-19-036489 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:08 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001209191-18-037788 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 12, 2018, with 100% of the total shares vested and exercisable on June 12, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 17:30 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-17-039876 · doc4.xml · derivative · entry 1 ONETTO NICOLE · CIK 0001220049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 13, 2017, with 100% of the total shares vested and exercisable on June 13, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.